NEW YORK, June 26, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Allergan plc (NYSE: AGN) on behalf of Allergan shareholders concerning the proposed merger with AbbVie Inc.
Click here to participate in the action.
Pursuant to the proposed transaction, announced on June 25, 2019 and valued at $63 billion, Allergan shareholders will receive 0.8660 shares of AbbVie common stock and $120.30 in cash for each Allergan share owned. The investigation focuses on whether Allergan and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company’s shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.
If you own Allergan shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 308-1869, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation of Allergan please go to https://bespc.com/agn/. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.